#Primary Sclerosing Cholangitis (PSC) epidemiology

[delveinsight12]

Primary Sclerosing Cholangitis Market Growth Anticipated: Primary Sclerosing Cholangitis Set for Robust Expansion up to 2032, Major Players Include HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics

In the market landscape of Primary Sclerosing Cholangitis, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled  “Primary Sclerosing Cholangitis Market Insights, Epidemiology and Market Forecast, 2032” from DelveInsight. Noteworthy advancements are projected, fueled not only by existing approved therapies but also by the introduction of emerging treatments slated for launch between 2023 and 2032, incremental increase in incidence is reported to impact the market significantly.

The report sheds light on Primary Sclerosing Cholangitis current treatment practices, upcoming drugs in the Primary Sclerosing Cholangitis pipeline, market shares of individual therapies, and the anticipated trajectory of the Primary Sclerosing Cholangitis market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Primary Sclerosing Cholangitis Market Growth

The overall market of Primary Sclerosing Cholangitis (PSC) is expected to boost due to the expected launch of emerging therapy in the forecasted period (2023–2032).

Discover the Anticipated Evolution and Growth of the Market @ Primary Sclerosing Cholangitis Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

Primary Sclerosing Cholangitis Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.

Primary Sclerosing Cholangitis Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Primary Sclerosing Cholangitis. Therapies such as HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and others are driving the Primary Sclerosing Cholangitis market.

Primary Sclerosing Cholangitis Epidemiological Trends and Patient Demographics:

According to DelveInsight analysis, in the US the diagnosed prevalence of Primary Sclerosing Cholangitis is higher in males than females.

According to DelveInsight analysis, in EU4 and the UK, the symptomatic cases of Primary Sclerosing Cholangitis are higher than asymptomatic cases. 

Report Features

Details

Geography Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Study Period

2019-2032

Market Size

~USD 113 million in 2022

Key Companies

HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others.

The market size of primary sclerosing cholangitis (PSC) is anticipated to increase during the study period, 2019–2032. The expected launch of therapies will lead to change in market dynamics during the forecast period (2023-2032).

Leading Primary Sclerosing Cholangitis Companies and Emerging Drugs: Pioneering companies such as HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, among others, are actively developing novel drugs for potential entry into the Primary Sclerosing Cholangitis market.

Primary Sclerosing Cholangitis Therapeutic Landscape: Key therapies identified for Primary Sclerosing Cholangitis treatment include HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and more.

Primary Sclerosing Cholangitis Overview:

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation, scarring (fibrosis), and narrowing of the bile ducts inside and outside the liver. Over time, this progressive condition can lead to liver damage, cirrhosis, and complications such as liver failure, bile duct infections (cholangitis), and an increased risk of bile duct and liver cancer (cholangiocarcinoma).

Cause: The exact cause of PSC is not fully understood. It is believed to involve an autoimmune component, where the body's immune system mistakenly attacks the bile ducts, leading to inflammation and scarring. PSC is also associated with other autoimmune conditions such as inflammatory bowel disease (IBD), particularly ulcerative colitis.

Symptoms: Many individuals with PSC initially have no symptoms (asymptomatic), but as the disease progresses, they may experience fatigue, itching (pruritus), jaundice (yellowing of the skin and eyes), abdominal pain, fever, weight loss, and complications related to bile duct obstruction or liver damage.

Diagnosis: Diagnosis of PSC involves a combination of blood tests, imaging studies (such as MRI or ERCP), and sometimes a liver biopsy to assess liver tissue for characteristic changes. Additionally, colonoscopy or other tests may be performed to evaluate for associated inflammatory bowel disease.

Treatment: There is no cure for PSC, and treatment primarily focuses on managing symptoms, slowing disease progression, and preventing complications. Medications may be prescribed to relieve itching, manage inflammation, and address complications. In some cases, endoscopic or surgical procedures may be necessary to relieve bile duct blockages.

Monitoring and Complications: Regular monitoring is crucial for individuals with PSC to assess disease progression, manage symptoms, and screen for complications such as liver cirrhosis, bile duct cancer, and other liver-related problems. Liver transplant may be considered for individuals with advanced PSC and severe liver damage or complications.

PSC is a chronic condition that requires ongoing care and monitoring by healthcare providers specializing in gastroenterology or hepatology. Management often involves a multidisciplinary approach, including gastroenterologists, hepatologists, surgeons, and other healthcare professionals, to address various aspects of the disease and optimize treatment strategies.

While treatment can help manage symptoms and slow disease progression, PSC is associated with a risk of complications and may require vigilant long-term management to improve quality of life and reduce the risk of serious liver-related issues.

Key Facts Primary Sclerosing Cholangitis Market Report:

The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

According to DelveInsight analysis, the United States accounted for the highest market size of $78 million, with significant market share of PSC in 2022 in the 7MM. The market size of the 7MM is anticipated to increase in the forecast period due to the expected launch of emerging therapy.

Among EU4 and the UK, Germany, Italy, and the UK accounted for the highest market size with approximately 25% each of the total market size in the EU4 and the UK in the year 2022, whileSpainaccounted for the lowest market in the year 2022.

As per DelveInsight estimates, the market size in Japan was approximately USD 4 million in 2022. These numbers are expected to increase during the forecasted period.

Primary Sclerosing Cholangitis Epidemiology Insights:

In 2022, there were about 9,171 diagnosed asymptomatic cases of PSC and 11,038 diagnosed symptomatic cases PSC, in the EU4 and the UK.

As per DelveInsight’s analysts, in Japan, there were approximately 2,443 diagnosed prevalent cases of PSC in the year 2022 accounting for nearly 5% of the total diagnosed prevalent cases of PSC in the 7MM.

Primary Sclerosing Cholangitis Epidemiology Segmentation:

The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Primary Sclerosing Cholangitis

• Prevalent Cases of Primary Sclerosing Cholangitis by severity

• Gender-specific Prevalence of Primary Sclerosing Cholangitis

• Diagnosed Cases oF Primary Sclerosing Cholangitis

For in-depth insights, access the full report @ Primary Sclerosing Cholangitis Market Outlook 2032

Related Reports:

Primary Sclerosing Cholangitis Epidemiology Forecast

Primary Sclerosing Cholangitis Epidemiology Forecast report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Primary Sclerosing Cholangitis Pipeline Insight

Primary Sclerosing Cholangitis Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 

Healthcare Consulting and Market Research Services by DelveInsight

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @  Healthcare Market Research Services

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Connect with DelveInsight:

LinkedIn | Facebook | Twitter

Contact Us:

Kritika Rehani

krehani@delveinsight.com

+91-9650213330

www.delveinsight.com

[kritikarehani]

Primary Sclerosing Cholangitis (PSC) Market Trends 2030

Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.

DelveInsight's "Primary Sclerosing Cholangitis (PSC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Primary Sclerosing Cholangitis (PSC) market report provides current treatment practices, emerging drugs, Primary Sclerosing Cholangitis (PSC) market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis (PSC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Primary Sclerosing Cholangitis (PSC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

· The United States

· EU5 (Germany, France, Italy, Spain, and the United Kingdom)

· Japan

Study Period: 2017-2030

Download sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market

Primary Sclerosing Cholangitis (PSC) Disease Understanding and Treatment Algorithm

Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition.  

The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen.

The DelveInsight Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Primary Sclerosing Cholangitis (PSC). 

Treatment 

It covers the details of conventional and current medical therapies available in the Primary Sclerosing Cholangitis (PSC) market for the treatment of the condition. It also provides Primary Sclerosing Cholangitis (PSC) treatment algorithms and guidelines in the United States, Europe, and Japan. 

Request for sample pages: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market

Primary Sclerosing Cholangitis (PSC) Epidemiology  

The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key facts:

• Primary sclerosing cholangitis is a rare disorder that affects males twice as often as females. Although it may affect individuals of any age, the disorder most often occurs in middle-aged adults.

• The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per each 100,000 in the general population in the United States or Europe.

Primary Sclerosing Cholangitis (PSC) Drug Chapters

In the coming years, the competitive landscape for the Primary Sclerosing Cholangitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  

Major players, such as Gilead Sciences, HighTide Therapeutics, Tobira Therapeutics and NGM Biopharmaceuticals are involved in developing therapies for Primary Sclerosing Cholangitis. Launch of emerging therapies, such as GS-9674 (Gilead Sciences), HTD1801 (HighTide Therapeutics), Cenicriviroc (Tobira Therapeutics) and NGM282 (NGM Biopharmaceuticals) will significantly impact the Primary Sclerosing Cholangitis market during the study period (2017–2030).  

Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Sclerosing Cholangitis (PSC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs 

The report provides the details of the marketed product available for Primary Sclerosing Cholangitis (PSC) treatment. 

Primary Sclerosing Cholangitis (PSC) Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Primary Sclerosing Cholangitis (PSC) treatment. 

Primary Sclerosing Cholangitis (PSC) Market Outlook

The treatment of PSC focuses on managing the complications and monitoring the liver damage. There have been several medications which are studied in people with Primary Sclerosing Cholangitis, but so far none have been found to slow or reverse the liver damage associated with this disease.

The pharmacotherapy is aimed at treating symptoms and managing complications. Immuno-suppressants, bile salts, chelators (eg, cholestyramine for pruritus), and steroids are used in an attempt to control the disease process but have not shown significant benefit. The further treatment depends on the stage and degree of progression of the disease. There are two major treatment goals in PSC: slow or reverse disease progression and management of symptoms of disease progression.

The Primary Sclerosing Cholangitis (PSC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis (PSC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Primary Sclerosing Cholangitis (PSC) market in 7MM is expected to change in the study period 2017-2030.

Click here and get access to our full report.

Click here and request to download our sample pages.

[kritikarehani]

Symptoms associated with Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.

Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition.  

The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen.

Source: https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market